Summit Therapeutics price to book ratio SMMT
Market value divided by the book value of the company's net assets, since 2020.
- Today, Nov 2, 2026
- 18.7×
- 6-year median
- 15.5×
- Against its 6-year history
- 55th
- percentile: 0 is its lowest day, 100 its highest
- 6-year range
- 1.2× to 183×
- Peer median
- 10.7×
Summit Therapeutics' price to book ratio is 18.7× as of Nov 2, 2026.
That is above its 6-year median of 15.5×, close to the middle of its last 6 years.
Over that time it ranged from 1.2× in Dec 2022 to 183× in Jul 2024.
The median for 10 large drugmakers of a similar size is 10.7×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 18.7× | 16.5× | 76.2× |
| 2025 | 70.2× | 30.1× | 76.4× |
| 2024 | 30.7× | 18.0× | 183× |
| 2023 | 18.4× | 2.3× | 18.4× |
| 2022 | 6.4× | 1.2× | 6.4× |
| 2021 | 2.6× | 2.6× | 20.0× |
| 2020 | 10.5× | 9.7× | 12.7× |
Against its peers
Companies in Drug Manufacturers - General nearest Summit Therapeutics' size, closest first, today.
| Company | Price to book ratio |
|---|---|
| SMMTSummit Therapeutics | 18.7× |
| BMRNBiomarin Pharmaceutical | 1.8× |
| JAZZJazz Pharmaceuticals | 2.9× |
| TGTXTG Therapeutics | 15.2× |
| PTGXProtagonist Therapeutics | 10.7× |
| CORTCorcept Therapeutics | 12.3× |
| ALKSAlkermes plc. | 4.2× |
| KNSAKiniksa Pharmaceuticals International | 10.8× |
| AMRXAmneal Pharmaceuticals | 198× |
| LGNDLigand Pharmaceuticals | 6.3× |
| INDVIndivior Pharmaceuticals | n/m |
| Peer median | 10.7× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on Summit Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.